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Abstract
Control of human cytomegalovirus (HCMV) depends on CD8+ T cell responses that are shaped by an individual’s repertoire
of MHC molecules. MHC class I presentation is modulated by a set of HCMV-encoded proteins. Here we show that HCMV
immunoevasins differentially impair T cell recognition of epitopes from the same viral antigen, immediate-early 1 (IE-1), that
are presented by different MHC class I allotypes. In the presence of immunoevasins, HLA-A- and HLA-B-restricted T cell
clones were ineffective, but HLA-C*0702-restricted T cell clones recognized and killed infected cells. Resistance of HLA-
C*0702 to viral immunoevasins US2 and US11 was mediated by the alpha3 domain and C-terminal region of the HLA heavy
chain. In healthy donors, HLA-C*0702-restricted T cells dominated the T cell response to IE-1. The same HLA-C allotype
specifically protected infected cells from attack by NK cells that expressed a corresponding HLA-C-specific KIR. Thus,
allotype-specific viral immunoevasion allows HCMV to escape control by NK cells and HLA-A- and HLA-B-restricted T cells,
while the virus becomes selectively vulnerable to an immunodominant population of HLA-C-restricted T cells. Our work
identifies a T cell population that may be of particular efficiency in HCMV-specific immunotherapy.
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Introduction
Human cytomegalovirus (HCMV) latently infects a majority of
humans for their lifetime. Infection is usually asymptomatic, but
can cause severe morbidity and mortality in immunocompromised
patients and after congenital or neonatal infection [1]. Cellular
immunity, and in particular the virus-specific CD8+ T cell
response, is of vital importance for controlling the virus [2]. For
example, after allogeneic stem cell transplantation, virus-specific
CD8+ T cells are associated with protection from HCMV disease
[3], and specific immunity in patients can be reconstituted by
adoptive transfer of virus-specific CD8+ T cells [4–6]. Congenital
HCMV infection has a higher frequency of causing harm when a
non-immune mother acquires the virus for the first time during
pregnancy [7], suggesting that pre-established maternal immunity
is partially protective. However, neither HCMV-specific adoptive
T cell therapy nor HCMV-specific vaccines [8,9] have moved
beyond the stage of clinical testing.
Various HCMV antigens are targeted by CD8+ T cells [10,11],
but only a small number of antigens elicit immunodominant
responses in a majority of healthy carriers [11,12]. Among these,
the 72-kDa immediate-early 1 protein (IE-1; UL123) deserves
attention. IE proteins are the first to be expressed in viral
replication [13] and initiate viral gene expression leading to virus
production. Therefore, IE-1-specific CD8+ T cells could poten-
tially control viral reactivation from latency before virus is
produced [14,15]. In murine CMV infection, IE-1-specific
CD8+ T cells are protective [16,17]. Although clinical responses
were also observed after transfer of T cells specific for other
HCMV antigens, in particular pp65 [4,6], CD8+ T cells specific
for IE-1 are associated with protection from viral disease or
reactivation in patients after different types of transplantation
[18,19]. A variety of IE-1 epitopes restricted through different
MHC class I (HLA-A and B) allotypes are recognized by CD8+ T
cells [10,20,21]. Therefore, IE-1 seems an attractive target of
HCMV-specific immunotherapy.
In spite of these arguments, the role of IE-1-specific CD8+ T
cells in control of HCMV has remained controversial, because it
was observed that their recognition of infected cells is strongly
inhibited [22] by a set of HCMV-encoded proteins that prevent
the presentation of viral peptides by MHC class I on the cell
surface [12,23]. In contrast, others have reported that IE-1-specific
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T cells efficiently recognize infected cells [24], although it is not
known which epitopes were responsible for this recognition.
Several immunoevasins encoded in the US2-11 region of the
HCMV genome interfere with antigen presentation on MHC class
I by preventing peptide transport (US6), retaining MHC molecules
in the endoplasmic reticulum (US3), or targeting them for
cytoplasmic degradation (US2, US11) [25–27]. Biochemical
studies have indicated that viral immunoevasins downregulate
the expression of different MHC class I allotypes to different
degrees [28,29]. However, it is not known whether such allotype-
specific variations in viral immunoevasion affect recognition of
infected cells by specific CD8+ T cells. For developing T cell
therapies and vaccines, the identification of HCMV peptide/
MHC class I complexes that are functionally recognized in spite of
viral immunoevasion would be important. To address these issues,
we analyze here the effect of HCMV immunoevasins on the
recognition of infected cells by IE-1-specific CD8+ T cell clones of
different HLA restrictions. Our results show that antigen
presentation to T cell clones representing a newly identified,
immunodominant HLA-C-restricted CD8+ T cell population, but
not to a panel of HLA-A- and HLA-B-restricted T cell clones, is
selectively preserved in infected cells. Conversely, killing of
infected cells by NK cells is inhibited by the same HLA-C
allotype. Thus, HCMV immunoevasion appears to exempt this
HLA-C allotype in order to avoid control by NK cells. As a
consequence, certain HLA-C-restricted CD8+ T cells efficiently
recognize IE-1 presented by infected cells. Such effectors may be
preferable targets of HCMV vaccine and immunotherapy.
Results
Identification of HLA-C-restricted IE-1-specific CD8+ T
cells
To obtain IE-1-specific CD8+ T cell lines containing various
epitope specificities and HLA restrictions in vitro, we restimulated
PBMCs from randomly chosen HCMV-positive donors with IE-1-
expressing mini-lymphoblastoid cell lines (mLCLs), as previously
reported for pp65 [30,31]. The resulting polyclonal T cell lines
were subjected to limiting dilution to obtain CD8+ T cell clones.
The IE-1 peptides recognized by these T cell clones were identified
using an overlapping 15-mer peptide library covering the IE-1
sequence [20]. Many CD8+ T cell clones from HLA-B*0702/
C*0702-positive carriers were specific for a nonameric IE-1-
derived peptide CRVLCCYVL (abbreviated CRV, amino acids
309–317) (Figure 1A). A variant peptide with the sequence
CRVLCCYIL, which is present in some HCMV strains including
Toledo and TB40E, was recognized with similar affinity
(Figure 1A). The CRV peptide was described earlier to be
restricted by HLA-B*07 [20]. Because this peptide lacks a proline
in position two, which is required for B*07-restricted peptides [32],
we tested the possibility that the peptide was instead restricted
through HLA-C*0702, an allele generally associated with HLA-
B*0702 in Europeans [33]. WI-38 fibroblasts were transfected with
HLA-B*0702 or -C*0702 and infected with pp65- or IE-1-
encoding modified vaccinia virus Ankara (MVA). The HLA-
B*0702-restricted pp65-derived epitope TPR [34] was recognized
by a specific T cell clone in HLA-B*0702-transfected but not in
HLA-C*0702-transfected targets (Figure 1B). Conversely, CRV-
specific T cell clones from different donors recognized IE-1 in the
context of HLA-C*0702, but not HLA-B*0702 (Figure 1C). CRV-
specific T cells recognized IE-1-expressing cells from various
C*0702-positive donors, but not cells from C*0701-positive or
other donors (Figure 1D). Thus, CRV is restricted through HLA-
C*0702, but not HLA-C*0701. This explains earlier observations
that responses to the CRV peptide were consistently found in
B*07/C*07-positive but not in B*08/C*07-positive donors [20],
because the former generally carry HLA-C*0702, the latter HLA-
C*0701 [33] (compare Table S1). These data show that HLA-C-
restricted IE-1-specific T cells are part of the T cell repertoire of
HCMV carriers.
Immunodominance of HLA-C*0702-restricted HCMV-
specific T cells
We analyzed the repertoire of IE-1-specific CD8+ T cells in
healthy HCMV carriers. T cells specific for the HLA-C*0702-
restricted peptide CRV could be directly detected in PBMCs of
15/15 HLA-C*0702-carrying donors by ELISPOT (Figure 2A),
with a mean frequency of 345 specific spots per 200 000 PBMCs
(range 29–837). Multimer staining (Figure 2B) showed that CRV/
C*0702-specific T cells were more frequent than TPR/B*0702-
specific T cells, a known immunodominant pp65 specificity [35].
Within IE-1, the region containing CRV was dominantly
recognized (Figure 2C), and CRV was the dominant IE-1 epitope
in 11 out of 15 donors (data not shown). In donors who were
HLA-A*0201 and HLA-C*0702-positive, CRV-specific T cells
were on average 3-fold more frequent than T cells specific for the
dominant A*0201-restricted epitope VLEETSVML (VLE) [21]
(Figure 2D). The total number of IE-1-reactive T cells was higher
in HLA-C*0702-positive donors than in HLA-C*0702-negative
donors (Figure 2E), mainly as a result of the high frequencies of
CRV-specific T cells.
CRV/C*0702 is recognized on infected cells by specific T
cells
The recognition of previously studied IE-1 epitopes by specific
T cells in HCMV-infected fibroblasts is severely suppressed [22]
due to the action of viral immunoevasive proteins that interfere
with MHC class I presentation [23], but there is evidence
suggesting that this may not uniformly be true for all IE-1 epitopes
[21,24]. We investigated whether recognition of infected fibro-
blasts by CRV/C*0702-specific T cells was similarly impaired. T
Author Summary
Human cytomegalovirus is very widespread. It cannot be
eliminated from the body. The health of its host depends
on immune responses that are maintained for a lifetime.
Virus-specific CD8-positive T cells recognize and kill
infected cells before they can produce more virus. Infected
cells are recognized because they display MHC class I
molecules that have bound a peptide derived from a viral
protein. The three most relevant human MHC I genes
(HLA-A, -B, -C) occur in many allelic variants that present
different viral peptides to different T cells. HCMV encodes
several molecules that interfere with stability or localiza-
tion of HLA class I, but it is unknown how this affects
recognition by T cells that recognize infection through
different HLA molecules. We show here for one viral
antigen, IE-1, that viral interference with T cell recognition
strongly depends on the identity of the HLA molecule:
HLA-A- and HLA-B-restricted T cells are fully inhibited, but
HLA-C-restricted T cells that target an epitope from the
same antigen recognize and kill infected cells with high
efficiency. Because this population of HLA-C-restricted T
cells has superior antiviral function and elevated frequency
in the blood, it may be particularly suitable for immuno-
therapy.
CD8+ T Cell Evasion by HCMV
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cell clones specific for A*0201-restricted epitopes NLV from pp65
and VLE from IE-1 were tested in parallel. Before infection with
HCMV strain AD169 at a multiplicity of infection (moi) of 5 or 10,
fibroblasts were cultivated in standard culture medium (Figure 3A)
or IFN-c-supplemented medium (Figure 3B). Recognition of
pp65/NLV/A*0201 was strong in the early stages of infection and
decreased over time, which is typical for abundant structural
antigens such as pp65 [36] that reach the infected cell as a part of
the virion. Recognition of the A*0201-restricted IE-1 epitope VLE
was abolished at all times in both conditions. In contrast, the
HLA-C*0702-restricted IE-1 epitope CRV was recognized on
infected fibroblasts at all times, with a maximum on days 2 and 3.
The kinetics of CRV presentation closely followed, with a 1-day
delay, the expected kinetics of IE-1 expression in infected
fibroblasts [37]. Upon pretreatment with IFN-c, recognition of
the pp65 epitope NLV and IE-1 epitope CRV in infected cells was
further increased without qualitatively altering the observed
recognition kinetics, while recognition of the IE-1 VLE epitope
was not rescued by IFN-c pretreatment. Thus, the CRV/C*0702
epitope escaped the immunoevasive mechanisms that prevented
the presentation of another IE-1 epitope in infected cells.
HCMV immunoevasins interfere with T cell recognition in
an allotype-specific manner
We studied the allotype-specific impact of HCMV immunoe-
vasins, employing a larger panel of IE-1-specific CD8+ T cell
clones with various HLA restrictions. Target cells were infected
with wild-type HCMV or an HCMV derivative deleted for the
four immunoevasins US2, US3, US6, and US11 (CMV-Dall).
Our analyses included IE-1-specific CD8+ T cell clones restricted
through HLA-A*0201, A*0301, A*6801, B*0801, B*4001, and
C*0702. Among 15 T cell clones with these 6 different HLA
restrictions, only the four C*0702-restricted clones showed a
distinct reactivity to HLA-matched fibroblasts infected with wild-
type HCMV (Figure 4). Although recognition of HLA-C*0702-
restricted antigen was weaker when the fibroblasts were not
pretreated with IFN-c (Figure 4B) than after such a pretreatment
(Figure 4A), preferential recognition of the HLA-C*0702-
restricted epitope as compared to all HLA-A- and B-restricted
epitopes was seen for both conditions. In contrast, infection with
the CMV-Dall virus was recognized by most T cell clones with
similar intensity irrespective of HLA restriction, and T cell
recognition after CMV-Dall infection was similar to recognition
after exogenous loading with peptide in each case. The
observation that all peptides were maximally presented after
CMV-Dall infection suggested that escape of HLA-C-restricted
presentation was not caused by a selective overabundance of
specific peptide that led to a saturation of immunoevasins, as
proposed for some epitopes in the mouse model [38], but was due
to the allotype-specific action of HCMV immunoevasins. Thus,
viral immunoevasins US2, 3, 6, and 11 completely blocked
antigen presentation by each of the HLA-A and HLA-B alleles
tested, but not by HLA-C*0702.
Figure 1. Identification of HLA-C*0702-restricted IE-1-specific CD8+ T cells. (A) Reactivity of T cell clone ALT#127 to titrated IE-1 peptides in
IFN-c ELISA (20 000 clonal T cells and 50 000 autologous peptide-loaded CD40-stimulated B cells per well in duplicates). (B, C) HLA restriction of the
IE-1 CRV epitope. WI-38 fibroblasts were transfected with HLA-B*0702 or C*0702 and infected with MVAs encoding pp65 (B) or IE-1 (C), alongside with
negative controls (no infection and wild-type (wt) MVA infection). Cells were then coincubated overnight with T cell clone F37#5 specific for pp65/
TPR/B*0702 (B) or IE-1/CRV-specific T cell clones (C) from 3 different donors (AJJ, AJU and ALT). For each condition, 10 000 fibroblasts and 10 000 T
cells were coincubated in 3 replicates. Supernatants were analyzed in an IFN-c ELISA. (D) The reactivity of T cell clone AJU#90 to IE-1-expressing or
control mini-LCLs from donors with various HLA types was tested in IFN-c ELISA (10 000 T cells and 20 000 mLCLs in two replicates). For full HLA class
I types, see Table S1.
doi:10.1371/journal.ppat.1003383.g001
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Next, we analyzed the role of individual HCMV immunoeva-
sins in modulating the presentation of different IE-1 epitopes by
infected cells. We infected fibroblasts with a set of HCMV mutant
viruses that expressed only one of the four immunoevasins US2, 3,
6, and 11, but were deleted for the other three [37,39,40], and
measured antigen presentation to CD8+ T cell clones specific for
the IE-1 epitopes CRV/C*0702 and VLE/A*0201 (Figure 5). In
this experiment, fibroblasts were pretreated with IFN-c before
infection. Under these conditions, each of the immunoevasins US2
and US11 was capable of downregulating the presentation of the
VLE/A*0201 epitope to near completion, whereas US3 and US6
did not have a major impact on the presentation of this epitope. In
contrast, none of the individual immunoevasins had a strong
inhibitory effect on the presentation of CRV/C*0702; a slight
effect of US2 and US11 seemed to be present, and the action of
these two immunoevasins may be mainly responsible for the
observed small reduction of CRV presentation after CMV wild-
type infection. This experiment showed that impairment of
antigen presentation by each of US2 and US11 is strongly
allotype-dependent: HLA-A*0201 is very efficiently targeted by
these immunoevasins, HLA-C*0702 is targeted to a very limited
extent.
To study the impact of individual HCMV immunovasins on
CD8+ T cell killing of infected cells, we employed HCMV strain
AD169 and its immunoevasin gene deletion variants CMV-Dall,
CMV-US2 and CMV-US11 (expressing only US2 or US11,
respectively, but not the other three of the standard set of
immunoevasins). Killing of infected cells by CD8+ T cells was
subject to the same allotype-specific patterns of immunoevasion as
was cytokine secretion (Figure 6), irrespective of pretreatment of
the infected cells with IFN-c. Killing by pp65-specific T cells was
not subject to strong immunoevasion, presumably because virion-
mediated antigen transfer led to presentation before immunoeva-
sins became active, as described above. HLA-A*0201-restricted
killing by IE-1-specific T cells was fully suppressed by the
combined HCMV immunoevasins, and largely so by each of the
individual proteins US2 or US11, in accordance with the results
obtained for cytokine secretion. In contrast, IE-1-specific, HLA-
C*0702-restricted killing was less than 50% impaired by the
assembled immunoevasins, and not at all by US2 or US11
individually.
Recognition of C*0702-presented antigen after infection
with endotheliotropic HCMV
So far, our analyses of antigen presentation by infected cells had
employed an established laboratory strain of HCMV, AD169, and
its derivatives. However, there are a number of genetic differences
between AD169 and low-passage clinical isolates of HCMV [41],
and this raised the question whether AD169 was fully represen-
tative of wild-type strains in terms of antigen presentation. Of
particular relevance, higher expression of the tegument protein
pp65 by AD169 than by low-passage isolates [42] could be
suspected to affect antigen presentation by competition of pp65
Figure 2. Immunodominance of CRV/C*0702-specific T cells. (A)
Frequencies of CRV-specific T cells in 15 HLA-C*0702-positive blood
donors, tested with the CRV nonameric peptide in ELISPOT assays. Black
parts of bars indicate CRV-specific signal, grey parts indicate background
(no peptide). (B) Specific T cells in PBMCs of HLA-C*0702 carriers were
quantified by fluorescent staining with HLA-C*0702/CRV streptamer or
HLA-B*0702/TPR pentamer and anti-CD8 antibody. Donors LT12 and
SA03 are HCMV-seropositive, donor ASM is HCMV-seronegative. (C)
Distribution of T-cell targets within the IE-1 sequence for 15 HLA-C*0702-
positive donors, tested with overlapping peptides covering the entire IE-
1 sequence of strain AD169. The 120 peptides were divided into 10
subpools, each comprising 12 successive 15-mer peptides with an
overlap of 11 amino acids. The C-terminal amino acid position of each
subpool is indicated. (D) Frequencies of CRV/C*0702-specific and VLE/
A*0201-specific T cells in HLA-C*0702/A*0201-positive donors (n= 6). (E)
Comparison of IE-1-specific T cell frequencies in C*0702-negative (n= 13)
vs. C*0702-positive (n= 15) donors. (A, C–E) IFN-c ELISPOT assays were
performed with 200 000 peptide-loaded PBMCs in each well and with 2–
4 replicates per condition.
doi:10.1371/journal.ppat.1003383.g002
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epitopes for certain MHC molecules, or due to other potential
immunoevasive functions of pp65 [43,44]. To address these
concerns, we performed T cell recognition experiments with
TB40-BAC4, a cloned derivative of endotheliotropic strain
TB40E, an HCMV strain that was described to be a valid
representative of clinical strains [45]. Of note, TB40-BAC4 lacks
the US2-6 region, which was deleted in the course of cloning
TB40E as a bacterial artificial chromosome; thus, only the US11
immunoevasin is expressed by this virus. Recognition experiments
were performed 2 days after infection with TB40-BAC4 (moi = 5),
under three different conditions of pretreatment with IFN-c,
which was added from 72 hours before infection, from 1 hour
after infection, or not added at any time (Fig. 7). Strikingly,
recognition of the pp65 epitope NLV/A*0201 was fully abolished
after infection with TB40-BAC4 under each condition, demon-
strating that a single immunoevasin, US11, is sufficient for full
repression of pp65 presentation by a recombinant clinical HCMV
strain. For the IE-1 epitopes VLE/A*0201 and CRV/C*0702,
our earlier experiments with AD169 derivatives were confirmed:
presentation of the VLE/A*0201 epitope was strongly suppressed
after TB40-BAC4 infection although only US11 was present,
whereas CRV/C*0702 presentation was present, and was fully
unimpaired in IFN-c-pretreated cells. Thus, allotype-specific
immunoevasion of IE-1 is not limited to a particular HCMV
strain, and the higher levels of pp65 in strain AD169 are unlikely
to suppress the presentation of IE-1 epitopes, which is in
agreement with earlier demonstrations that pp65 does not
suppress recognition of IE-1 [21,24]. Moreover, pp65 is presented
by a recombinant HCMV field strain with unexpectedly low
efficiency. The experiment also demonstrates that the variant
CRVLCCYIL present in some HCMV strains (such as TB40E,
Toledo, Davis) is as efficiently presented as the CRVLCCYVL
variant present in other strains (such as AD169, Merlin, Towne,
strain W), and the same T cell clones recognize both variants.
There is little variation in the US11 protein sequence among
HCMV strains: only two amino acids are not identical among the
four strains Merlin, Toledo, AD169 and TB40E (S42 in AD169,
P42 in Merlin, Toledo, and TB40E; I102 in Merlin, V102 in
AD169, Merlin and Toledo). Similarly, the US2 sequences of
Merlin and Toledo differ from AD169 US2 only in a substitution
(E46Q) affecting an amino acid that does not interact with the
HLA heavy chain [46]. Therefore, it is likely that the
immunoevasins of other HCMV strains have an allotype-specific
function that is similar to the viruses AD169 and TB40-BAC4 that
Figure 3. Time course of pp65- and IE-1-specific CD8+ T cell recognition of HCMV-infected fibroblasts. pp65 and IE-1 T cell epitopes
were analyzed for their HLA-A*0201 or -C*0702-restricted presentation to T cell clones at different time points post infection. MRC-5 fibroblasts (HLA-
A*0201, C*0702) were not treated (A) or were treated (B) with IFN-c for 72 hours prior to infection with HCMV AD169 at an moi of 5 or 10. At the
indicated time points post infection, 10 000 fibroblasts were incubated with 10 000 T cells for 16–18 hours before measuring antigen-specific IFN-c
secretion by ELISA assay. Cells that were not infected (n.i.) or were peptide-loaded 48 hours post infection (+pep) served as controls. Data are shown
as mean+SD of triplicate samples. One of three independent experiments with clones ALT#21 NLV, F61#38 VLE and AJJ#7 CRV is shown,
representing experiments with a total of 3 NLV-, 6 VLE- and 12 CRV-specific T cell clones, from 3 different donors for each specificity.
doi:10.1371/journal.ppat.1003383.g003
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were experimentally tested here, and that CRV-specific T cells
recognize HCMV IE-1 irrespective of strain variations.
As a further test for a potential interfering role of pp65, we
compared the presentation of HCMV epitopes after infection with
AD169 wild-type virus and with its pp65-deleted derivative [47].
Deletion of pp65 had no impact on the differential recognition of
the IE-1 epitopes VLE/A*0201 and CRV/C*0702 (Figure S1),
ruling out a role for pp65 in allotype-specific immunoevasion of
IE-1 epitopes in accordance with earlier observations [21,24].
Antigen presentation and viral destabilization are
mediated by separate domains of HLA class I
Our T cell experiments showed that HLA-C*0702 and HLA-
A*0201 were functionally affected to a very different degree by
US2 and US11. These viral glycoproteins interact with different
domains of the MHC heavy chains studied so far: US2 with amino
acids near the boundary of the a2 and a3 domains, US11 with
regions in the a1/a2 domains and, more importantly, in the
cytosolic tail of the HLA molecule [48,49]. We wished to assess
whether antigen presentation to CD8+ T cells and destabilizing
interactions with HCMV immunoevasins were separable proper-
ties of these two extreme instances of HLA class I molecules, HLA-
C*0702 and HLA-A*0201, and whether immunoevasion was
independent of the presented peptide. To this purpose, we
constructed chimeric HLA heavy chains (Figure 8A) that
contained the N-terminal part of one of these HLA allomorphs
(comprising the a1/a2 domains that bind and present peptide) and
the C-terminal part of the other allomorph (comprising the a3
domain, transmembrane region and cytosolic tail). WI-38 fibro-
blasts, which are negative for HLA-A*0201 and -C*0702, were
transfected with constructs encoding parental or chimeric HLA,
infected with MVA-IE-1, and tested for recognition by IE-1-
specific T cells (Figure 8B). The HLA-A*0201-restricted VLE
peptide was only recognized on HLA-A*0201 and chimeric HLA-
A2/C7, whereas the C*0702-restricted CRV peptide was only
recognized on HLA-C*0702 and chimeric HLA-C7/A2, confirm-
ing that the chimeric molecules fully and specifically presented
their cognate antigen. We then tested the effects of US2 and US11
on antigen presentation by native and chimeric HLA molecules in
the context of HCMV infection (Figure 8C). As seen before, T cell
recognition of HLA-A*0201 and HLA-C*0702 epitopes was
differentially affected by different HCMV strains in cells trans-
fected with native MHC class I genes: recognition of VLE/A*0201
was strongly reduced by wild-type CMV, CMV-US2, or CMV-
US11, whereas recognition of CRV/C*0702 was not impaired by
CMV-US2 or CMV-US11 and only partially by wild-type CMV
infection. Strikingly, in the chimeric A2/C7 or C7/A2 molecules a
complete exchange of the patterns of sensitivity to HCMV
immunoevasins was observed. Thus, while the a1/a2 domains
present antigen to T cells, the C-terminal part including the a3
domain largely governs the sensitivity of MHC class I to HCMV
immunoevasins, and these functions are separable and exchangeable.
Figure 4. Collective impact of HCMV immunoevasins on the recognition of IE-1 T cell epitopes with different HLA restrictions.
Fibroblasts were infected with HCMV AD169 (CMV-wt) or an AD169 variant lacking the four immunoevasins US2, 3, 6, and 11 (CMV-Dall). Recognition
by various IE-1 epitope-specific T cell clones with the indicated specificities was analyzed. To cover every required HLA allotype, three primary
fibroblast cell lines were used: MRC-5 (C*0702, A*0201), WI-38 (A*6801, B*0801), BFF2 (A*0301, B*4001). Fibroblasts were precultured in the presence
(A) or absence (B) of IFN-c for 72 hours, then infected at moi = 5 and cocultivated with T cells at 48 hours post infection (10 000 fibroblasts and
10 000 T cells per well). IFN-c secretion was measured by ELISA. Targets included cells that were not infected (n.i.) or peptide-loaded (n.i. +peptide).
One to four representative T cell clones of each specificity were analyzed. Data are shown as mean+SD of triplicate samples. One representative of
three independent experiments is shown.
doi:10.1371/journal.ppat.1003383.g004
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In addition, this experiment showed that the differences in epitope
presentation by HLA-C*0702 and HLA-A*0201 were not caused by
different processing efficiencies of the bound peptides, in contrast to
previous observations concerning MCMV epitopes [50].
HCMV-infected fibroblasts inhibit HLA-C*0702-sensitive
NK cells
The selective preservation of antigen presentation by HLA-
C*0702 on infected cells was unexpected, because it should
facilitate T cell attack in vivo. We considered whether the
maintenance of HLA-C*0702 conferred an advantage to HCMV.
HLA-C allomorphs are ligands for inhibitory killer-cell immuno-
globulin-like receptors (KIRs) expressed by NK cells. We tested
whether HLA-C*0702 on infected cells prevented their NK cell-
mediated killing. We established NK cell lines and clones that
uniformly expressed KIR2DL3, a receptor for group 1 HLA-C
allotypes including HLA-C*0702. NK cells were obtained from a
donor homozygous for group 1 HLA-C alleles to ensure maximal
functional competence of KIR2DL3-positive NK cells [51].
Infection experiments were performed in MRC-5 fibroblasts that
express HLA-C*0702 as their only KIR2DL3 ligand. Polyclonal
NK cells contained 99.1% of KIR2DL3-positive cells; expression
of other relevant NK receptors was minor (KIR2DL1+, 1.1%;
KIR3DL1+, 3.9%; NKG2A+, 1.7%; Figure 9A). In parallel, NK
cell clones were established that were KIR2DL3+ KIR2DL12
KIR3DL12 NKG2A2 (Figure 9B). Polyclonal and monoclonal
NK cells killed MHC class I-deficient cell lines (K562, Daudi and
L721.221) and HLA-C*0602-expressing but not HLA-C*0702-
expressing L721.221 cells (Figure 9C, D). Accordingly, blocking of
HLA-C*0702 on transfected L721.221 cells with anti-HLA-ABC
antibody restored NK cell-mediated lysis (Figure 9G). Killing of
HCMV-infected or uninfected MRC-5 fibroblasts was low,
irrespective of their IFN-c pretreatment (Figure 9E, F), suggesting
that an inhibitory ligand was present on these target cells. Blocking
of HLA-ABC on fibroblasts or of KIR2DL3 on NK cells induced
killing of uninfected and HCMV-infected fibroblasts (Figure 9G).
These results indicate that HLA-C*0702, the only ligand of
KIR2DL3 present in this system, prevented an attack on HCMV-
infected fibroblasts by NK cells expressing this inhibitory receptor.
Presumably, HCMV preserves HLA-C*0702 on infected cells in
order to evade killing by NK cells.
Discussion
Here we show that MHC class I allotype-specific immunoeva-
sion by HCMV strongly influences CD8+ T cell recognition of
infected cells. In particular, IE-1-specific CD8+ T cells that are
restricted through a frequent HLA-C allotype, HLA-C*0702,
recognize infected cells much more efficiently than HLA-A- and
HLA-B-restricted T cells, and presentation of their target epitope
resists HCMV immunoevasion in an allotype-specific manner. At
the same time, infected cells were resistant to NK cells carrying
KIR2DL3, an inhibitory receptor specific for certain HLA-C
allotypes including C*0702. These results prompt us to speculate
that a requirement to balance first-line defense by NK cells and
long-term control by HLA-A- or HLA-B-restricted CD8+ T cells
may have influenced the evolution of a complex repertoire of
allotype-specific HCMV immunoevasins. As a result, certain
HLA-C-restricted CD8+ T cells have particularly efficient
antiviral function. Such CD8+ T cells dominated the response to
IE-1 in most carriers of this HLA-C allele, suggesting that they
may be particularly useful in immunotherapy.
Relationships between immunodominance, epitope processing
and epitope presentation in the face of viral immunoevasion have
been previously studied in the mouse model. Murine CMV elicits
CD8+ T cell responses against two epitopes from the antiapoptotic
protein M45, an immunodominant Db-restricted epitope and a
subdominant Dd-restricted epitope. While presentation of the
dominant epitope is fully abolished in the presence of viral
immunoevasins, leading to non-protectivity of the corresponding
Db-restricted specific T cells in vivo [52], the subdominant epitope
from the same antigen is presented more efficiently in the presence
of viral immunoevasins and mediates protection in vivo [50].
Analyses of the amounts of intracellularly retained peptides led to
the conclusion that the Dd peptide was more efficiently processed
than the Db peptide, and this difference in processing was
responsible for the better presentation of the Dd peptide [50].
Although we could not directly assess the processing efficiency of
the different IE-1 epitopes in HCMV-infected cells, our domain-
swapping experiments show that not the a1/a2 domains or the
peptide bound by them, but the C-terminal part of MHC class I
molecules guided allotype-specific suppression of antigen presen-
tation by HCMV immunoevasins. Thus, while it is possible that
different IE-1 peptides are processed with different efficiencies,
such a differential processing was not responsible for differential
presentation of the A*0201/C*0702 pair. Moreover, differential
availability of other IE-1 epitopes appears unlikely because all
tested IE-1 epitopes were presented with approximately equal,
near-maximal efficiency in cells that were infected with immu-
noevasin-deleted HCMV. Because the IE-1 epitope that is most
Figure 5. Impact of individual HCMV immunoevasins on the
recognition of IE-1 T cell epitopes. MRC-5 fibroblasts were infected
with HCMV strain AD169 (wt), with AD169 derivative viruses that
expressed only one of the four immunoevasins US2, US3, US6, or US11
as indicated, not infected (n.i.) or peptide-loaded (+pep), and their
recognition by T cell clones specific for the IE-1 epitopes CRV/C*0702
and VLE/A*0201 was analyzed. Before infection, fibroblasts were
precultured with IFN-c for 72 hours, then infected at moi = 5 and
cocultivated with T cells at 48 hours post infection (10 000 fibroblasts
and 10 000 T cells per well). IFN-c secretion was measured by ELISA.
Data are shown as mean+SD of triplicate samples. Representative data
are shown for one of 10 CRV-specific clones and one of 4 VLE-specific
clones, assayed in two independent experiments.
doi:10.1371/journal.ppat.1003383.g005
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efficiently presented in the presence of immunoevasins is also the
most immunodominant one, HLA-C*0702-restricted IE-1-specific
T cells will be easily available or inducible in immunotherapeutic
settings. Studies of larger panels of epitopes that include other
HCMV antigens will show whether other immunodominant
epitopes exist whose presentation is similarly efficient. Infection
studies in different cell types other than fibroblasts will provide a
more comprehensive picture of HCMV immunoevasion, in order
to explain the priming and sustenance of T cells specific for
epitopes whose presentation is abolished in fibroblasts. Such future
analyses may address, for example, whether antigen presentation
by directly infected hematopoietic cells [53] is more resistant to
HCMV immunoevasins than antigen presentation by fibroblasts,
or whether cross-presentation [54] is required for some epitopes to
circumvent immunomodulation by HCMV.
A variety of factors may be important in shaping the
immunodominance of certain T cells over others. For example,
HLA-A*0201-restricted T cell responses to the pp65 antigen from
HCMV are numerically smaller in carriers who additionally
express HLA-B*0702, an allotype that drives strong pp65-specific
T cell responses [55]. This suggests that allotype-specific
competition for antigen at the T cell population level influences
the composition of T cell repertoires. One antigen of particular
interest in this context will be pp65, considering that we
unexpectedly found a very low level of presentation of the HLA-
A*0201-restricted pp65 epitope NLV by cells infected with the
endotheliotropic HCMV derivative TB40-BAC4. The lower levels
of pp65 that are expressed by endotheliotropic strains [42], which
are considered more representative of HCMV field strains than
strain AD169, may render pp65 presentation susceptible to
HCMV immunoevasins, potentially resulting in allotype-specific
hierarchies of presentation efficiencies that are similar to the one
we observed here for IE-1. Conversely, it is possible that cell types
other than fibroblasts will present antigens such as pp65 more
efficiently in the presence of HCMV immunoevasins.
The importance of HCMV immunoevasins was recently
highlighted by the observation that their homologs promote in
vivo evasion of CD8+ T cells in a primate model [56]. It seems
reasonable to assume that, in humans, CD8+ T cell evasion of
HCMV is strongly affected by the diversity of MHC allotypes.
However, previous studies on MHC class I allotype-specific effects
of HCMV immunoevasins (see below) have been limited to
molecular or phenotypic investigations of transfected or trans-
duced cells. Our study provides the first systematic analysis of
MHC class I allotype-specific effects of HCMV immunoevasins on
CD8+ T cell recognition of infected cells, employing an extended
set of CD8+ T cell clones that recognize peptides from the same
HCMV antigen, presented by a variety of different human class I
allotypes. Although we did not directly demonstrate that the T cell
clones studied by us were representative for T cells of the same
specificity in vivo, we consider this very likely, because different T
cell clones of the same epitope specificity from different donors
Figure 6. Effect of HCMV immunoevasins on epitope-specific T cell cytotoxicity. MRC-5 fibroblasts (HLA-A*0201, C*0702) were
preincubated in medium with (A) or without (B) IFN-c for 72 hours before infection at moi = 5 with AD169 (CMV-wt) or its derivatives CMV-Dall (DUS2/
3/6/11), CMV-US11 (DUS2/3/6) or CMV-US2 (DUS3/6/11). Cytotoxicity was determined at 48 hours post infection in a 3.5-hour calcein release assay
using an effector:target ratio of 4. Fibroblasts that were not infected (n.i.) or peptide-loaded (n.i. +peptide) were negative and positive controls,
respectively. Data are shown as mean+SD of three to four replicates.
doi:10.1371/journal.ppat.1003383.g006
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consistently displayed the same patterns of antigen recognition and
its modulation (for example, for the CRV/C*0702 epitope this
was true for 21 tested T cell clones from four donors). Our
functional data show that allotype-specific HCMV immunoeva-
sion has strong repercussions on T cell recognition of infected cells,
and resolve some contradictions between earlier studies. As a case
in point, HLA-C expression was moderately reduced when US3 or
US6 [57], but not when US2 or US11 [29] were overexpressed in
trophoblasts. Our data show that the action of all these viral
immunoevasins, when expressed from the viral genome in infected
cells, is not sufficient to abolish antigen presentation by HLA-
C*0702, strongly supporting the hypothesis that HLA-C/peptide
complexes presented by infected placental cells are likely to be a
target of cytotoxic T cells [29], and refuting the notion that viral
immunoevasion will prevent such a recognition [57]. Molecular
elements of HLA molecules that influence their direct or indirect
allotype-specific interaction with HCMV immunoevasins have
been studied for US2 [49], US3 [58,59], and US11 [49].
However, such interactions have often appeared to be guided by
rather complex rules. This was particularly the case for US11,
where variations both in the cytosolic tail and in the a1/a2
domains of HLA molecules were described to influence their
allotype-specific downregulation following complex combinatory
patterns [60]. None of these studies addressed whether their
observed effects had an impact on T cell recognition. Our data
show that such complications can be resolved when the
biologically relevant read-out, functional T-cell recognition, is
directly studied. Our domain-swapping experiments performed
with HLA-A*0201 and C*0702 demonstrated that the a1/a2
domains of HLA molecules mediated antigen recognition, whereas
the a3 domain and C-terminal region guided allotype-specific
immunoevasion, both for US2 and US11 individually and for
US2/3/6/11 in aggregate.
NK cell activity is regulated by MHC class I allele-specific
signals. The HLA-C/KIR system represents one of the most
general mechanisms of human NK cell control: every HLA-C
allotype can provide an inhibitory signal through at least one KIR,
and every human KIR haplotype encodes KIRs specific for each
of the two existing groups of HLA-C [61]. Although NK cell
reactivity to HCMV-infected cells is modulated by additional
inhibitory and activating NK receptors that are targeted by a
multitude of HCMV proteins [62], our experiments indicate that
inhibitory signaling through HLA-C and an inhibitory KIR
(KIR2DL3) can protect infected fibroblasts from NK cell
recognition. Surprisingly, the idea that the downregulation of
classical MHC class I molecules shapes NK cell recognition of
HCMV-infected cells is controversial, being supported by some
[63–65] but contested by other studies [66–68]. Allotype-specific
downregulation of MHC class I can explain such contrasting
interpretations. For example, Falk et al. [63] demonstrated that
Figure 7. Presentation of IE-1 to CD8+ T cells after infection with endotheliotropic HCMV. MRC-5 fibroblasts were infected with HCMV
TB40-BAC4, not infected (n.i.) or peptide-loaded (n.i.+peptide), and their recognition by T cell clones specific for the pp65 epitope NLV/A*0201 and
the IE-1 epitopes CRV/C*0702 and VLE/A*0201 was analyzed. Fibroblasts were cultured in standard medium alone (A), with IFN-c from 1 hour after
infection (B), or were pretreated with IFN-c 72 hours before infection (C). Infection was performed at moi = 5, and effector assays were set up
48 hours post infection (10 000 fibroblasts and 20 000 T cells per well). IFN-c secretion was measured by ELISA. Data are shown as mean+SD of
triplicate samples.
doi:10.1371/journal.ppat.1003383.g007
CD8+ T Cell Evasion by HCMV
PLOS Pathogens | www.plospathogens.org 9 May 2013 | Volume 9 | Issue 5 | e1003383
NK lysis was induced after fibroblast infection with wild-type but
not US2-11 deleted HCMV. Because the relevant receptor-ligand
pair in this study was KIR2DL2 and (likely) HLA-C*0701, this
rises the interesting possibility that the two major HLA-C*07
allotypes are differentially regulated by HCMV infection, with
different effects on NK cell recognition in carriers of different
Figure 8. Functional separation of epitope presentation and HCMV immunoevasion. WI-38 fibroblasts (negative for HLA-A*0201 and
C*0702) were transfected with plasmids encoding HLA-A*0201, HLA-C*0702, or chimeric HLA class I heavy chains (HLA-A2/C7 or HLA-C7/A2) and
subsequently infected with MVA-IE-1 or different HCMV derivatives. IFN-c secretion was measured in ELISA after overnight incubation of 10 000
clonal T cells with 10 000 target cells. (A) Schematic representation of the native and chimeric HLA class I molecules that were tested. (B) HLA-
transfected WI-38 cells were infected with MVA-IE-1, and presentation of IE-1 epitopes was detected by VLE- and CRV-specific T cell clones. Mean and
SD of three replicates are shown for 3 T cell clones generated from 3 different donors for each specificity. (C) HLA-transfected WI-38 were infected
with CMV-wt, CMV-Dall, CMV-US2 or CMV-US11, not infected (n.i.) or peptide-loaded (+pep). Three T cell clones generated from 3 different donors
were used as effectors for each specificity. Data are shown as mean+SD of triplicate samples from one of two independent experiments.
doi:10.1371/journal.ppat.1003383.g008
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alleles. Others suggested that KIRs and MHC class I do not play a
role in NK recognition of HCMV-infected fibroblasts [68], but did
not address the role of individual KIR-HLA pairings in the context
of infection. In this context, the enigmatic observation that a
majority of NK cell clones from two donors had indifferent
reactivity to non-infected and infected autologous fibroblasts [66]
can now be explained by the fact that both donors happened to be
carriers of HLA-C*0702, leading to HLA-C*0702-mediated
inhibition of NK cell reactivity via KIR2DL3 as demonstrated
in our study. Taken together, the degree of downregulation of
HLA-C allotypes by HCMV may be an important factor in
modulating the activity of NK cells in response to infection in a
particular carrier.
The present data exemplify the importance of HLA-C in
presentation of viral antigens and its important contribution to
antiviral T cell repertoires. A special antiviral role of HLA-C due
to allotype-specific immunoevasion was previously shown for HIV:
the selective downregulation of HLA-A and B, but not C, protects
HIV-infected cells against NK cells but sensitizes them to HLA-C-
restricted CD8+ T cells [69,70], and genotypic data showed that
certain HLA-C alleles are associated with better control of HIV
[71]. Analogously, certain HLA allotypes could potentially
predispose to an improved control of HCMV infection. The role
of HLA-C-restricted CD8+ T cells in prevention of congenital
HCMV infection and pregnancy loss could be of particular
importance [29], because placental cells express HLA-C, but not
HLA-A or -B [57]. Hypothetically, the existence of an HLA-
C*0702-restricted HCMV epitope that mediates superior recog-
nition of infection might be one of the factors that contribute to
selection for the high frequency of this allotype in different human
Figure 9. HLA-mediated inhibition of NK cell recognition of HCMV infection. Experiments were performed with polyclonal NK cells (A, C, E,
G) or NK cell clone #29 (B, D, F, G) from donor AJU. (A, B) Analysis of KIR expression by flow cytometry. (C, D) Killing by NK cells of the MHC class I-
deficient cell lines K562, Daudi and L721.221, HLA-C*0602 or C*0702-transfected L721.221 cells, uninfected MRC-5 fibroblasts, or MRC-5 infected with
CMV-wt at moi = 5, at an effector:target ratio of 2. Data are shown as mean+SD of four replicates from one representative experiment out of four. (E,
F) NK cell-mediated killing of uninfected (n.i.) and HCMV-infected fibroblasts over time after infection. Fibroblasts were or were not pretreated with
IFN-c before infection as indicated. (G) Blockade of NK cell mediated-killing by monoclonal antibodies specific for HLA-ABC or KIR2DL2/3 (both IgG2a)
or a matched isotype control. Targets were pretreated with IFN-c. Blockade of the non-KIR ligand HLA-A2 served as additional negative control. The
HLA class I type of MRC-5 fibroblasts is HLA-A*0201, A*2902, B*0702, B*4402, C*0501, C*0702. HLA-C*0702 is the only ligand of KIR2DL3 expressed by
MRC-5 cells. Killing was assessed at an effector:target ratio of 2. Data are shown as mean+SD of triplicate samples from one out of two independent
experiments.
doi:10.1371/journal.ppat.1003383.g009
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populations around the world [29], in whom it represents the most
frequent HLA-C allotype with phenotypic frequencies of 30–40%
[33,72]. Further studies may show whether particular MHC class I
allotypes or certain HLA/KIR combinations provide a selective
advantage due to better defense against the ubiquitous pathogen
HCMV, and whether HLA-C-restricted T cells will prove to be
particularly efficient effectors in immunotherapy.
Materials and Methods
Ethics statement
Mononuclear cells from standard blood donations by anony-
mous healthy adult donors were obtained from the Institute for
Transfusion Medicine, University of Ulm, Germany. The
institutional review board (Ethikkommission, Klinikum der Uni-
versita¨t Mu¨nchen, Grosshadern, Munich, Germany) approved this
procedure. All work was conducted according to the principles
expressed in the Helsinki Declaration.
Cells and peptides
HLA typing of blood donations was performed by PCR-based
methods (IMGM, Martinsried, Germany). HLA-A, -B and -C
alleles and HCMV IgG serostatus (Max von Pettenkofer Institute,
Munich, Germany) of the donors are listed in Table S1. Standard
cell culture and PBMC preparation was performed as described
[73]. Mini-lymphoblastoid cell lines (mLCLs) stably expressing
HCMV IE-1, pp65 or no heterologous antigen were generated by
infection of PBMCs with B-cell transforming mini-Epstein-Barr
virus (mini-EBV) [30]. CD40-stimulated B cell cultures were
established and maintained as described [74]. Human fetal lung
fibroblast lines MRC-5 and WI-38 were obtained from the
European Collection of Animal Cell Cultures (ECACC). BFF2 is a
primary human foreskin fibroblast line. Their HLA class I types
are as follows: MRC-5, HLA-A*0201, A*2902, B*0702, B*4402,
C*0501, C*0702; WI-38, A*0205, A*6801, B*0801, B*5801,
C*0701; BFF2, A*0201, A*0301, B*3501, B*4001, C*0304,
C*1502. L721.221 cells and their derivatives stably transfected
with HLA-C*0602 or -C*0702 [75] were kindly provided by
Elfriede No¨ßner (Munich). K562 and Daudi cells were from the
American Type Culture Collection (ATCC).
Peptides were synthesized to .70% purity by JPT (Berlin),
resuspended in 100% dimethyl sulfoxide (DMSO) and stored at
220uC. DMSO concentration in all T cell effector assays was kept
below 0.1% (vol/vol). The frequency and specificity of IE-1-
specific T cells was analyzed by using a library of 120 peptides,
each 15 amino acids in length, spanning the entire IE-1 sequence
of HCMV strain AD169, with subsequent peptides overlapping in
11 amino acids.
Recombinant and chimeric MHC class I molecules
HLA-A*0201, -B*0702 and -C*0702 sequences were amplified
by PCR from cDNA prepared from HLA-typed LCLs. PCR
products were cloned into the vector pCMVcyto (Invitrogen).
Plasmids pCMV-HLA-A*0201 and pCMV-HLA-C*0702 were
used for the construction of the HLA chimera HLA-A2/C7 (aa
224 to 175 of HLA-A*0201 and 176 to 342 of HLA-C*0702) and
its counterpart HLA-C7/A2 (aa 224 to 175 of HLA-C*0702 and
176 to 341 of HLA-A*0201). These switched chimeras were
constructed using an Esp3I restriction site in a conserved region
near the C-terminal end of the a2-domain.
Fibroblasts were transfected with HLA-encoding plasmids using
the Amaxa Cell Line Nucleofector Kit R and Nucleofector I
Device (program V-01) (Lonza). Plasmid pEGFP-C1 (BD Biosci-
ences) was used as a transfection control and demonstrated
transfection rates of 60–70%. After 24 hours, 200 mg/mL G-418
were added (Invitrogen). Fibroblasts were infected with MVA or
HCMV on day 4 and used in T cell effector assays 24 or 48 hours
later.
Viruses
Modified vaccinia virus Ankara (MVA) recombinants express-
ing either pp65, IE-1 or no HCMV antigen were kindly provided
by Naeem Khan (Birmingham, UK) and propagated on baby
hamster kidney (BHK-21) cells [12]. For T-cell assays with MHC
class I-transfected fibroblasts, cells were infected with MVAs at ten
50% infectious tissue culture dose (TCID50) units per cell for
24 hours.
HCMV strain AD169 was kindly provided by Martin Messerle
(Hannover, Germany), TB40-BAC4 [45] by Barbara Adler
(Munich, Germany). AD169 mutant viruses that lacked the four
immunoevasins US2, US3, US6, and US11 (CMV-Dall =RV-
KB6) or expressed only one of them, only US11 (CMV-
US11=RV-KB9, deletion of US2, US3 and US6), only US2
(CMV-US2=RV-KB13, deletion of US3, US6 and US11), only
US3 (CMV-US3) or only US6 (CMV-US6), were generated by
BAC mutagenesis by successive deletion of individual coding
sequences [37,40]. The AD169 mutant deleted for pp65 (CMV-
Dpp65=RVAd65) was described previously [47]. Stocks of
HCMV strains and mutants were prepared by infection of
semiconfluent MRC-5 cells at an moi of 0.1. After 14–18 days,
supernatants were harvested, cleared from cellular debris by
centrifugation, aliquoted and stored at 280uC. Virus titers were
determined by infection of MRC-5 cells in flat-bottom 96-well
plates at limiting dilution. For T cell effector assays, fibroblasts
were precultivated with 300 U/ml recombinant human IFN-c
(PAN Biotech) for 72 hours before infection, cultivated with IFN-c
1 hour after infection, or not treated with IFN-c as indicated.
Infection with all HCMVs was performed at an moi of 5 for
48 hours, unless indicated otherwise.
T cells
IE-1- or pp65-specific T cell lines were prepared by restimu-
lation of PBMCs from HCMV-seropositive donors with irradiated
(50 Gy) autologous mLCLs expressing the appropriate HCMV
antigen [31]. T cell clones were obtained by limiting dilution of
these T cell lines or, in some cases, directly from PBMCs after
peptide stimulation and IFN-c secretion assay (Miltenyi Biotec). T
cells (0.7 or 2.5 cells/well) were seeded into round-bottom 96-well
plates (200 mL/well) in medium supplemented with 1000 U/mL
rIL-2, 16105/mL irradiated (50 Gy) HLA-matched pp65- or IE-
1-expressing mLCLs and 1.56106/mL of a mixture of irradiated
(50 Gy) allogeneic PBMCs from at least three different donors.
Outgrowing T cell clones were expanded in round-bottom 96-well
plates by restimulating every 2 weeks under the same conditions.
The T cell clones were specific for the following epitopes:
NLVPMVATV (pp65, A*0201) [76,77], TPRVTGGGAM
(pp65, B*0702) [34,77], ATTFLQTMLR (IE-1, A*6801) [35],
KEVNSQLSL (IE-1, B*4001) [35], QIKVRVDMV (IE-1,
B*0801) [10], VLEETSVML (IE-1, A*0201) [21], CRVLCCYVL
(IE-1, C*0702) and RIKEHMLKK (IE-1, A*0301) (unpublished).
T-cell effector assays
PBMCs were analyzed for specific IFN-c secretion in ELISpot,
T cell clones in ELISA and cytolysis assays. In any of these assays,
antigenic peptides were used whenever indicated at final
concentrations of 5 mg/mL per peptide when using single peptides
or subpools of up to 12 peptides, and 0.5 mg/mL/peptide when
using the complete pool of 129 IE-1 peptides. IFN-c ELISpot
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analyses (Mabtech, Nacka, Sweden) were performed in 96-well
MultiScreen HTC Filter Plates (Millipore). After antibody coating
of the wells, 200 000 PBMCs were distributed to each well,
directly loaded with antigenic peptide, and incubated in a total of
200 mL medium per well for 16–18 hours at 37uC and 5% CO2.
After counterstaining with biotinylated secondary antibody and
streptavidin-AP, spots were developed using the AP Conjugate
Substrate Kit from Bio-Rad and visually counted after scanning.
To quantify IFN-c secretion by T cell clones as a measure of
antigen recognition [73], effector cells (1–26104/well, as indicat-
ed) were cocultivated for 16–18 h with target cells (1–56104/well,
as indicated) in 200 mL/well of V-bottom 96-well plates at 37uC
and 5% CO2. Supernatants were harvested and IFN-c ELISA was
performed (Mabtech, Nacka, Sweden).
Lysis of HCMV-infected fibroblasts by CD8+ T cell clones was
analyzed by calcein-release assay [73]. Infected or control
fibroblasts were washed with PBS and detached by trypsinization.
Target cells (1–26106) were labeled with 5 mg/mL calcein
acetoxymethylester (Invitrogen) in 500 mL medium for 30 minutes
at 37uC. After washing three times with PBS, 5000 targets/well
were co-incubated with 20 000 clonal T cells/well or 40 000
polyclonal T cells/well in V-bottom 96-well plates in a total
volume of 200 mL/well. For each type of target, spontaneous
release (no T cells added, 0% lysis) and maximal release (0.5% of
Triton-X100 added, 100% lysis) was determined. After 3.5 hours
of incubation at 37uC and 5% CO2, 150 mL/well of supernatant
was transferred to a flat-bottom 96-well plate, and fluorescence
intensity at 485/535 nm (excitation/emission) was measured in a
Wallac Victor counter (Perkin-Elmer).
Flow cytometry
CD8+ T cells specific for the HLA-B*0702-restricted TPR
epitope or the HLA-C*0702-restricted CRV epitope were
quantified with MHC class I multimer reagents. CRV-specific
CD8+ T cells were stained using MHC OneSTrEPtag-Strep-Tactin
multimers [78]. CRV/HLA-C*0702 OneSTrEPtag monomers
were prepared as described [79]. For multimerization, monomers
were incubated with PE-labeled Strep-Tactin (IBA, Go¨ttingen) for
45 minutes at a 1:1 molar ratio. Then, 56105 PBMCs were
incubated with an aliquot of the assembled streptamer reagent
containing 2.5 mg HLA-C*0702 monomer in a total volume of
30 ml PBS+2% FCS for 30 minutes on ice. Cells were counter-
stained by adding CD8-APC (BioLegend) to the streptamer
staining mixture and incubating for 20 minutes on ice. For
quantification of TPR-specific T cells, 56105 PBMCs were
incubated with 1 mL HLA-B*0702/TPR pentamer (Proimmune,
Oxford, UK) for 10 minutes at room temperature. After washing
with PBS+2% FCS, T cells were counterstained with pentamer-
binding Pro5 Fluorotag R-PE (Proimmune) and CD8-APC
(BioLegend) for 20 minutes on ice.
To characterize NK cells, the following antibodies were used:
CD56-PE-Cy5 (clone HCD56, BioLegend), KIR2DL1-FITC
(clone HP-3E4, BD Pharmingen), KIR2DL2/3-PE (clone CH-L,
BD Pharmingen), KIR3DL1-FITC (clone DX9, BioLegend),
NKG2A-APC (clone 131411, Beckman Coulter).
After staining, cells were washed with PBS+2% FCS and fixed
with 1% formaldehyde (Carl Roth). Cells were analyzed on a BD
Biosciences FACSCalibur flow cytometer. Data analysis was
performed using FlowJo 9.4.11 software (Tree Star).
NK cells
Donor AJU was positive for KIRs 2DL1, 2DL3, 2DL4, 2DS4,
3DL1, 3DL2, 3DL3, and negative for KIRs 2DL2, 2DL5, 2DS1,
2DS2, 2DS3, 2DS5, 3DS1 (IMGM, Martinsried, Germany).
KIR2DL3-expressing NK cells from PBMCs of donor AJU were
enriched by immunomagnetic depletion of CD3+ cells with CD3
MicroBeads (Miltenyi Biotec) followed by positive isolation using
PE-labeled anti-KIR2DL2/3 antibody (clone CH-L, BD Phar-
mingen) and anti-PE MicroBeads (Miltenyi). KIR2DL3-enriched
NK cells were expanded in bulk and, in parallel, under conditions
of limiting dilution. In both cases, NK cells were cultivated in
round-bottom 96-well plates (200 mL/well) in standard cell culture
medium supplemented with 500 U/mL rIL-2 and restimulated
every two weeks with a feeder mixture consisting of 26105/mL
irradiated (50 Gy) HLA-C1 group-positive allogeneic mLCLs and
16106/mL irradiated (50 Gy) allogeneic PBMCs from at least
three different donors.
Killing by NK cells was analyzed by calcein-release assay [73] at
an effector/target ratio of 2/1. To mask MHC class I molecules on
target cells, purified HLA-ABC- (W6/32, IgG2a) or HLA-A2-
(BB7.2, IgG2b) specific antibodies (BioLegend) were added at
60 mg/mL to the target cells for 1 hour at 37uC prior to addition
of effector cells. To inhibit KIR2DL2/3 interaction with its MHC
class I ligands, NK cells were preincubated with an antibody
blocking KIR2DL2/3 (clone DX27, IgG2a, BioLegend) at 60 mg/
mL for 1 hour at 37uC. Purified mouse IgG2a and IgG2b
(BioLegend) were used as isotype controls.
Supporting Information
Table S1 HLA types and HCMV carrier states of
donors.
(PDF)
Figure S1 Impact of pp65 on the presentation of IE-1
epitopes by infected cells. Fibroblasts were pretreated with
IFN-c for three days and infected with CMV strain AD169
(CMV-wt) or an AD169 mutant deleted for the pp65 gene. One
day after infection, recognition of infected cells by clonal CD8+ T
cells with the indicated specificities was tested in an IFN-c ELISA
at an effector target ratio of 1:1 (A) and a cytotoxicity assay at an
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